Display options
Cite
Esfahani K, Agulnik JS, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol. 2014;4:174doi: 10.3389/fonc.2014.00174.
Esfahani, K., Agulnik, J. S., & Cohen, V. (2014). A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in oncology, 4174. https://doi.org/10.3389/fonc.2014.00174
Esfahani, Khashayar, et al. "A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer." Frontiers in oncology vol. 4 (2014): 174. doi: https://doi.org/10.3389/fonc.2014.00174
Esfahani K, Agulnik JS, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol. 2014 Jul 21;4:174. doi: 10.3389/fonc.2014.00174. eCollection 2014. PMID: 25101240; PMCID: PMC4104550.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2014 Jul 21;4:174. doi: 10.3389/fonc.2014.00174. eCollection 2014.

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers in oncology

Khashayar Esfahani, Jason Scott Agulnik, Victor Cohen

Affiliations

  1. Department of Oncology, Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital , Montreal, QC , Canada.
  2. Division of Pulmonary Diseases, Department of Oncology, Peter Brojde Cancer Center , Montreal, QC , Canada.

PMID: 25101240 PMCID: PMC4104550 DOI: 10.3389/fonc.2014.00174

Abstract

The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4-ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.

Keywords: ALK-inhibitors; anaplastic lymphoma kinase; clinical trials as topic; crizotinib; driver mutations; non-small cell lung cancer

References

  1. Clin Cancer Res. 2012 Nov 15;18(22):6219-26 - PubMed
  2. Sci Transl Med. 2012 Feb 8;4(120):120ps2 - PubMed
  3. Cancer Res. 2010 Dec 1;70(23):9827-36 - PubMed
  4. Clin Cancer Res. 2012 Sep 1;18(17):4682-90 - PubMed
  5. N Engl J Med. 2013 Jun 20;368(25):2395-401 - PubMed
  6. Cancer Res. 2011 Sep 15;71(18):6051-60 - PubMed
  7. Curr Opin Oncol. 2014 Mar;26(2):159-64 - PubMed
  8. Lancet Oncol. 2013 Jun;14(7):590-8 - PubMed
  9. Clin Cancer Res. 2009 May 1;15(9):3143-9 - PubMed
  10. Genomics. 2013 Sep;102(3):157-62 - PubMed
  11. N Engl J Med. 2014 Mar 27;370(13):1189-97 - PubMed
  12. Cancer Discov. 2013 Apr;3(4):430-43 - PubMed
  13. Lung Cancer. 2014 May;84(2):110-5 - PubMed
  14. Nat Med. 2013 Nov;19(11):1389-400 - PubMed
  15. J Clin Oncol. 2013 Nov 1;31(31):3987-96 - PubMed
  16. Chem Biol Drug Des. 2011 Dec;78(6):999-1005 - PubMed
  17. J Thorac Oncol. 2013 May;8(5):574-81 - PubMed
  18. Cancer Res. 2011 Jul 15;71(14):4920-31 - PubMed
  19. Clin Cancer Res. 2012 Mar 1;18(5):1472-82 - PubMed
  20. J Thorac Oncol. 2013 Sep;8(9):e85-6 - PubMed
  21. BMC Res Notes. 2013 Nov 26;6:489 - PubMed
  22. N Engl J Med. 2010 Oct 28;363(18):1734-9 - PubMed
  23. Lung Cancer. 2014 Jan;83(1):37-43 - PubMed
  24. Clin Cancer Res. 2013 Jun 1;19(11):3068-77 - PubMed
  25. J Thorac Oncol. 2013 Apr;8(4):e32-3 - PubMed
  26. BMC Cancer. 2013 Oct 10;13:471 - PubMed
  27. J Clin Oncol. 2011 May 20;29(15):e443-5 - PubMed
  28. J Clin Oncol. 2010 Nov 20;28(33):4953-60 - PubMed
  29. Cancer Cell. 2011 May 17;19(5):679-90 - PubMed
  30. Clin Cancer Res. 2011 Dec 1;17(23):7394-401 - PubMed
  31. Clin Cancer Res. 2013 Aug 1;19(15):4273-81 - PubMed
  32. Drugs. 2013 Dec;73(18):2031-51 - PubMed
  33. N Engl J Med. 2013 Jun 20;368(25):2385-94 - PubMed
  34. Nature. 2007 Aug 2;448(7153):561-6 - PubMed
  35. Cancer Res. 2010 Dec 15;70(24):10038-43 - PubMed
  36. J Thorac Oncol. 2013 Apr;8(4):415-22 - PubMed
  37. Front Oncol. 2012 May 11;2:41 - PubMed
  38. Cancer Biol Ther. 2014 May;15(5):570-7 - PubMed
  39. Bioorg Med Chem. 2012 Feb 1;20(3):1271-80 - PubMed
  40. Sci Transl Med. 2012 Feb 8;4(120):120ra17 - PubMed
  41. N Engl J Med. 2010 Oct 28;363(18):1693-703 - PubMed

Publication Types